Evidence map›Paper›PMID 30199576›Full record

ArticleHepatology (Baltimore, Md.)2019

A Long Noncoding RNA Regulates Hepatitis C Virus Infection Through Interferon Alpha-Inducible Protein 6.

Xiao Liu, Xiaoqiong Duan, Jacinta A Holmes, Wenting Li, Sae Hwan Lee, Zeng Tu, Chuanlong Zhu, Shadi Salloum, Anna Lidofsky, Esperance A Schaefer and 11 more

Abstract read
In one paragraph

Article in Hepatology (Baltimore, Md.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 66 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Epigenetic Mechanisms Involved in Hcv Infection and Human HCC.International journal of molecular sciences · 2025
    Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 8 institutions in 4 countries.

Xiao LiuCollege of Animal Science and Technology, Southwest University, Chongqing, China.
Xiaoqiong DuanInstitute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking Union Medical College, Chengdu, China.
Jacinta A HolmesLiver Center and Gastrointestinal Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Wenting LiLiver Center and Gastrointestinal Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Sae Hwan LeeLiver Center and Gastrointestinal Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Zeng TuLiver Center and Gastrointestinal Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Chuanlong ZhuLiver Center and Gastrointestinal Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Shadi SalloumLiver Center and Gastrointestinal Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Anna LidofskyLiver Center and Gastrointestinal Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Esperance A SchaeferLiver Center and Gastrointestinal Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Dachuan CaiLiver Center and Gastrointestinal Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Shilin LiInstitute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking Union Medical College, Chengdu, China.
Haoju WangCollege of Animal Science and Technology, Southwest University, Chongqing, China.
Yongfu HuangCollege of Animal Science and Technology, Southwest University, Chongqing, China.
Yongju ZhaoCollege of Animal Science and Technology, Southwest University, Chongqing, China.
Ming-Lung YuLiver Center and Gastrointestinal Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Zhiwen XuAnimal Biotechnology Center, College of Veterinary Medicine, Sichuan Agricultural University, Chengdu, China.
Limin ChenInstitute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking Union Medical College, Chengdu, China.
Jian HongLiver Center and Gastrointestinal Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Wenyu LinInstitute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking Union Medical College, Chengdu, China.
Raymond T ChungLiver Center and Gastrointestinal Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Harvard University · USChinese Academy of Medical Sciences & Peking Union Medical College · CNMassachusetts General Hospital · USSouthwest University · CNAnhui Medical University · CNChongqing Medical University · CNKaohsiung Medical University · TWSichuan Agricultural University · CN

Funding

Virology CoreU19AI082630 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI RAYMOND T CHUNG, GEORG Michael LAUER · 2009 to 2026
$48.1M
Pilot & Feasibility ProgramP30DK043351 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI RAYMOND T CHUNG · 1991 to 2026
$35.3M
HIV-Hepatitis C Virus Cooperative Interactions and Liver Disease ProgressionR01DK098079 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI CHUNG, RAYMOND T · 2013 to 2016
$2.7M
HIV-Hepatitis C Virus Interactions and PathogenesisR01AI069939 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI CHUNG, RAYMOND T · 2006 to 2010
$1.9M
HIV-Associated Macrophage Alterations and Progressive Liver DiseaseR01DK108370 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI CHUNG, RAYMOND T · 2015 to 2019
$1.6M
HIV-Hepatitis C Virus Cooperative Interactions and Liver Disease ProgressionR56DK098079 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI CHUNG, RAYMOND T · 2012 to 2012
$506k
CAMS Initiative for Innovative Medicine 2017-I2M-B&R-15CAMS Initiative for Innovative Medicine CAMS-2016-I2M-3-025China Scholarship CouncilChongqing Social Undertakings and the People's Livelihood Security Program cstc2018jscx-msyb0797Doctoral Fund of Southwest University 22300501Fundamental Research Funds for the Central Universities 2120134708Fundamental Research Funds for the Central Universities XDJK2017A003National Natural Science Foundation of China 81871661NIAID NIH HHS R01 AI069939NIAID NIH HHS U19 AI082630NIDDK NIH HHS P30 DK043351NIDDK NIH HHS R01 DK098079NIDDK NIH HHS R01 DK108370NIDDK NIH HHS R56 DK098079NSFC 31772564
6 · The paper itself

Abstract

Long noncoding RNAs (lncRNAs) play a critical role in the regulation of many important cellular processes. However, the mechanisms by which lncRNAs regulate viral infection and host immune responses are not well understood. We sought to explore lncRNA regulation of hepatitis C virus (HCV) infection and interferon response. We performed RNA sequencing (RNAseq) in Huh7.5.1 cells with or without interferon alpha (IFNα) treatment. Clustered regularly interspaced short palindromic repeats/Cas9 guide RNA (gRNA) was used to knock out selected genes. The promoter clones were constructed, and the activity of related interferon-stimulated genes (ISGs) were detected by the secrete-pair dual luminescence assay. We constructed the full-length and four deletion mutants of an interferon-induced lncRNA RP11-288L9.4 (lncRNA-IFI6) based on predicted secondary structure. Selected gene mRNAs and their proteins, together with HCV infection, in Huh7.5.1 cells and primary human hepatocytes (PHHs) were monitored by quantitative real-time PCR (qRT-PCR) and western blot. We obtained 7,901 lncRNAs from RNAseq. A total of 1,062 host-encoded lncRNAs were significantly differentially regulated by IFNα treatment. We found that lncRNA-IFI6 gRNA significantly inhibited HCV infection compared with negative gRNA control. The expression of the antiviral ISG IFI6 was significantly increased following lncRNA-IFI6 gRNA editing compared with negative gRNA control in Japanese fulminant hepatitis 1 (JFH1)-infected Huh7.5.1 cells and PHHs. We observed that lncRNA-IFI6 regulation of HCV was independent of Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling. lncRNA-IFI6 negatively regulated IFI6 promoter function through histone modification. Overexpression of the truncated spatial domain or full-length lncRNA-IFI6 inhibited IFI6 expression and increased HCV replication. Conclusion: A lncRNA, lncRNA-IFI6, regulates antiviral innate immunity in the JFH1 HCV infection model. lncRNA-IFI6 regulates HCV infection independently of the JAK-STAT pathway. lncRNA-IFI6 exerts its regulatory function via promoter activation and histone modification of IFI6 through its spatial domain.

Indexed as

Cells, CulturedHepacivirusHepatitis CHumansInterferon-alphaRNA, Long NoncodingIFNA6 protein, humanInterferon-alphaRNA, Long Noncoding

Identifiers

PMID30199576
PMCPMC6393205
OpenAlexW2892210799

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.